1-4 of 4
Aspasia Stamatoulas, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience

Virginie Chesnais, Aline Renneville, Andrea Toma, Veronique Sardnal, Marie Passet, Audrey Gauthier, Jacques Delaunay, MD, Aspasia Stamatoulas, MD, Odile Beyne-Rauzy, MDPhD, Pierre Fenaux, MD PhD, Francois Dreyfus, MD, Claude Preudhomme, PharmD, PhD, Olivier Kosmider, MD PhD, Michaela Fontenay
Journal: Blood
Blood (2014) 124 (21): 533.
https://doi.org/10.1182/blood.V124.21.533.533
Published: 2014
Journal Articles

Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure

Thomas Prebet, MD, PhD, Thorsten Braun, Odile Beyne-Rauzy, Eric Wattel, MD, PhD, Francois Dreyfus, Aspasia Stamatoulas, MD, Shanti Ame, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Fatiha Chermat, Pierre Fenaux, Norbert Vey
Journal: Blood
Blood (2012) 120 (21): 3825.
https://doi.org/10.1182/blood.V120.21.3825.3825
Published: 2012
Journal Articles

Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

Marc PE André, MD, Oumedaly Reman, MD, Massimo Federico, MD, Théodore Girinski, MD, Pauline Brice, MD, Ercole Brusamolino, MD, Christophe Ferme, MD, Richard vander Maazen, MD, Monica Bellei, Catherine Sebban, MD, Franck Morschhauser, MD, PhD, Elly Lugtenburg, MD, PhD, Aspasia Stamatoulas, MD, Catherine Fortpied, Msc, Michel Meignan, MD, PhD, Annibale Versari, MD, Martin Hutchings, MD, John Raemaekers, MD
Journal: Blood
Blood (2012) 120 (21): 549.
https://doi.org/10.1182/blood.V120.21.549.549
Published: 2012
Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Simone Boehrer, MD, Odile Beyne-Rauzy, MD, Thomas Prebet, M.D., Ph.D., Sophie Park, MD, PhD, Agnès Guerci, MD, Aspasia Stamatoulas, MD, MP Chaury, MD, Tony Jernival, Laurence Sanhes, MD, Gerard Tertian, MD, Stephane Cheze, MD, Eng-Mong Lim, Bachra Choufi, MD, Denis Caillot, MD, E. Wattel, MD, Jacques Delaunay, MD, Laurence Legros, MD, Fatiha Chermat, Françoise Isnard, MD, N. Cambier, MD, Borhane Slama, MD, Lydia Roy, MD, Gandhi Damaj, MD, Emmanuel Raffoux, MD, Francois Dreyfus, MD, Christian Récher, MD, Norbert Vey, MD, Sylvie Chevret, PhD, Pierre Fenaux, MD, PhD, Claude Gardin, MD
Journal: Blood
Blood (2010) 116 (21): 1880.
https://doi.org/10.1182/blood.V116.21.1880.1880
Published: 2010